Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT04855656

Public ClinicalTrials.gov record NCT04855656. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

Study identification

NCT ID: NCT04855656
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Debiopharm International SA; Industry
Enrollment: 464 participants

Conditions and interventions

Conditions

Advanced Solid Tumor

Interventions

Debio0123 Drug
Lunresertib Drug
RP-3500 Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 29, 2021
Primary completion: Nov 30, 2027
Completion: May 31, 2028
Last update posted: Apr 19, 2026

2021 – 2028

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 15

Facility	City	State	ZIP	Site status
# 1019, UCLA, Westwood Cancer Center	Los Angeles	California	90095	Completed
#1025, University of California San Francisco	San Francisco	California	94158	Recruiting
#1012, Yale	New Haven	Connecticut	06520	Recruiting
#1017, Mayo Clinic	Jacksonville	Florida	32224	Recruiting
#1002, Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
#1023, START Midwest	Grand Rapids	Michigan	49503	Recruiting
#1016, Mayo Clinic	Rochester	Minnesota	55902	Recruiting
#1011, Washington University	St Louis	Missouri	63130	Recruiting
#1032, Northwell Health Cancer Institute	New Hyde Park	New York	11042	Recruiting
#1008, Columbia University	New York	New York	10032	Completed
#1004, Memorial Sloan Kettering Cancer Institute	New York	New York	10065	Recruiting
#1010, University of Pennsylvania	Philadelphia	Pennsylvania	19104	Completed
#1007, Rhode Island Hospital	Providence	Rhode Island	02903	Recruiting
#1030, Women & Infants Hospital of Rhode Island	Providence	Rhode Island	02903	Recruiting
#1001, The University of Texas M.D. Anderson Cancer Center	Houston	Texas	77030	Recruiting
#1013, The University of Utah	Salt Lake City	Utah	84112	Recruiting
#1027, University of Virginia	Charlottesville	Virginia	22903	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04855656, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 19, 2026 · Synced Apr 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04855656 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →